Cadila Pharmaceuticals Strengthens India–Russia Healthcare Ties

Cadila Pharmaceuticals Limited continues to strengthen its global footprint by actively participating in high-level India–Russia business and healthcare forums. Through strategic dialogues with government leaders and industry stakeholders, Cadila Pharma has reaffirmed its long-term commitment to advancing affordable and high-quality healthcare solutions while deepening bilateral cooperation between India and Russia.

Cadila Pharmaceuticals at the Russia–India Business Forum 2025

Cadila Pharmaceuticals participated in the Russia–India Business Forum 2025, a significant platform aimed at enhancing bilateral collaboration across key sectors, including healthcare and pharmaceuticals. The forum was accompanied by a high-level ministerial delegation and senior industry leaders from both nations, highlighting the strategic importance of Indo-Russian partnerships in healthcare innovation and manufacturing.

Representing Cadila Pharmaceuticals, Dr. Raj Prakash Vyas, Group President – Corporate & Public Affairs, engaged in strategic discussions with H.E. Mr. Sergey Glagolev, Deputy Minister of Healthcare of the Russian Federation. These discussions focused on emerging areas of cooperation, regulatory collaboration, and long-term opportunities to strengthen healthcare ecosystems across both countries.

Dr. Vyas’s participation further reinforced Cadila Pharmaceuticals’ commitment to India’s global health diplomacy and its vision to contribute meaningfully to the evolving Russia–India healthcare partnership.

India–Russia Business Dialogue 2023: A Foundation for Strategic Growth

Cadila Pharmaceuticals’ engagement with Russia is built on strong foundations laid during the India–Russia Business Dialogue held in New Delhi on 17th April 2023. During this high-powered bilateral industrial roundtable, Cadila Pharmaceuticals met:

• H.E. Mr. Denis Manturov, Hon’ble Deputy Prime Minister and Minister for Industry & Trade, Russian Federation
• H.E. Dr. S. Jaishankar, Hon’ble External Affairs Minister, Government of India

The dialogue enabled joint exploration of collaboration and investments within the healthcare ecosystem of both countries, aligning policy vision with industry capability.

Proposed Injectable Manufacturing Facility for the Russian Market

During the 2023 dialogue, Cadila Pharmaceuticals announced its plans to set up a state-of-the-art pharmaceutical injectable manufacturing facility in collaboration with Russia. The proposed facility aims to:

• Meet global regulatory and quality compliance standards
• Strengthen local manufacturing capabilities
• Deliver affordable healthcare solutions to the US $30 billion Russian healthcare market

On behalf of Cadila Pharmaceuticals, Mr. Raj Prakash Vyas, President – Corporate Affairs, interacted with senior ministers and industry leaders and also participated as a Key Speaker at the Inaugural Session. He emphasized Cadila Pharma’s long-standing credibility, research-driven approach, and trust built across global markets.

Strategic Engagements with Moscow Government Leaders

The business dialogue was also attended by H.E. Mr. Sergey Cheremin, Chairman of the Board of the Business Council for Cooperation with India and Minister of the Department of Foreign Economic Activity and International Relations, Moscow City Government.

Mr. Cheremin expressed strong appreciation for Cadila Pharma’s guiding philosophy – “The Care Continues….” and its mission to provide affordable healthcare globally. Impressed by Cadila’s innovative and research-driven product portfolio, he invited Cadila Pharmaceuticals for a one-to-one strategic meeting to discuss:

• Ease of Doing Business initiatives by the Moscow Government
• Opportunities for pharmaceutical and injectable manufacturing
• Expansion potential in Pharmaceuticals and Herbal (Ayurveda) businesses in Moscow, Russia

These interactions opened pathways for deeper collaboration and long-term business expansion in the Russian market.

Cadila Pharmaceuticals’ Vision for Global Healthcare Partnerships

Cadila Pharmaceuticals’ engagement across these high-level forums demonstrates its strategic vision to collaborate with global governments and healthcare systems. By leveraging India’s pharmaceutical expertise and Russia’s growing healthcare demand, Cadila Pharma aims to:

• Enhance access to quality medicines
• Support healthcare self-reliance through local manufacturing
• Strengthen international healthcare ecosystems through innovation and trust

About Cadila Pharmaceuticals Limited

Cadila Pharmaceuticals Limited is one of India’s leading integrated, privately held pharmaceutical companies, headquartered in Ahmedabad, Gujarat. The company develops, manufactures, and markets pharmaceutical products across 100+ countries worldwide.

Cadila Pharmaceuticals places a strong emphasis on research and innovation, spanning:

• Biotechnology
• Active Pharmaceutical Ingredients (APIs)
• Finished formulations
• Plant tissue culture
• Phytochemistry

The company’s research-driven portfolio addresses multiple therapeutic areas, including gastrointestinal, cardiology, pulmonary, oncology, gynaecology, cardiovascular, diabetology, and osteology. Guided by its mission to create affordable healthcare solutions for unmet medical needs, Cadila Pharmaceuticals has achieved several world-first breakthroughs, reinforcing its role as a trusted global healthcare partner.

Why This News Matters for Global Healthcare

Cadila Pharmaceuticals’ active participation in India–Russia healthcare dialogues is a strong indicator of India’s growing leadership in global pharmaceutical manufacturing and innovation. With Russia emerging as a key market for affordable and quality medicines, such collaborations are expected to:

• Improve patient access to essential injectable medicines
• Encourage cross-border technology transfer
• Strengthen regulatory cooperation between India and Russia
• Support sustainable and compliant pharmaceutical manufacturing

As geopolitical and healthcare priorities evolve, partnerships like these position Cadila Pharmaceuticals as a trusted global healthcare partner.